Global X Ownership
| GNOM Etf | USD 10.08 0.25 2.54% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Global |
Global Etf Ownership Analysis
Global X is is formed as Regulated Investment Company in the United States. ETF is managed and operated by Global X Management Company LLC. The fund has 44 constituents across multiple sectors and instustries. The fund charges 0.5 percent management fee with a total expences of 0.5 percent of total asset. The fund retains 99.96% of assets under management (AUM) in equities. The fund invests at least 80 percent of its total assets in the securities of the underlying index. Gx Genomics is traded on NASDAQ Exchange in the United States. To learn more about Global X Genomics call the company at NA or check out http://www.completegenomics.com.Sector Exposure (%)
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Global Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Global X , and the less return is expected.
Currency Exposure (%)
Investment Allocations (%)
Top Etf Constituents
| ILMN | Illumina | Stock | |
| VRTX | Vertex Pharmaceuticals | Stock | |
| VCYT | Veracyte | Stock | |
| SRPT | Sarepta Therapeutics | Stock | |
| RARE | Ultragenyx | Stock | |
| QURE | Uniqure NV | Stock | |
| QGEN | Qiagen NV | Stock | |
| PTCT | PTC Therapeutics | Stock | |
| PACB | Pacific Biosciences of | Stock | |
| NTRA | Natera Inc | Stock | |
| NTLA | Intellia Therapeutics | Stock | |
| NSTG | NanoString Technologies | Stock | |
| A | Agilent Technologies | Stock | |
| EDIT | Editas Medicine | Stock | |
| CRSP | Crispr Therapeutics AG | Stock | |
| CDNA | Caredx Inc | Stock | |
| BPMC | Blueprint Medicines Corp | Stock | |
| BOLD | Boundless Bio, Common | Stock | |
| BMRN | Biomarin Pharmaceutical | Stock | |
| BLUE | Bluebird bio | Stock | |
| BEAM | Beam Therapeutics | Stock | |
| ARWR | Arrowhead Pharmaceuticals | Stock | |
| ALNY | Alnylam Pharmaceuticals | Stock | |
| ALLO | Allogene Therapeutics | Stock |
Global X Genomics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Global X insiders, such as employees or executives, is commonly permitted as long as it does not rely on Global X's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Global X insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Caskey C Thomas over a month ago Disposition of 3307 shares by Caskey C Thomas of Global X subject to Rule 16b-3 | ||
Highland Capital Management Lp over three months ago Acquisition by Highland Capital Management Lp of 233402 shares of Global X subject to Rule 16b-3 | ||
Orbimed Advisors Llc over three months ago Disposition of 474800 shares by Orbimed Advisors Llc of Global X at 2.5106 subject to Rule 16b-3 | ||
Orbimed Advisors Llc over six months ago Acquisition by Orbimed Advisors Llc of 1267070 shares of Global X subject to Rule 16b-3 | ||
Caskey C Thomas over six months ago Disposition of 833 shares by Caskey C Thomas of Global X subject to Rule 16b-3 |
Global X Outstanding Bonds
Global X issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Global X Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Global bonds can be classified according to their maturity, which is the date when Global X Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| GLOBAL PARTNERS LP Corp BondUS37954FAG90 | View | |
| US37954FAJ30 Corp BondUS37954FAJ30 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US37959EAA01 Corp BondUS37959EAA01 | View | |
| GL 48 15 JUN 32 Corp BondUS37959EAB83 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Global X Genomics. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
The market value of Global X Genomics is measured differently than its book value, which is the value of Global that is recorded on the company's balance sheet. Investors also form their own opinion of Global X's value that differs from its market value or its book value, called intrinsic value, which is Global X's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Global X's market value can be influenced by many factors that don't directly affect Global X's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Global X's value and its price as these two are different measures arrived at by different means. Investors typically determine if Global X is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Global X's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.